一项评估不良事件及口服ABBV-1042在健康成年受试者体内代谢过程的研究
一项评估ABBV-1042在健康受试者中单次递增剂量给药的安全性、耐受性及药代动力学的1期、双盲、安慰剂对照、首次人体试验
This study will assess the adverse events, tolerability, and how oral ascending doses of ABBV-1042 moves through the body of healthy adult participants.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Illinois
-
Grayslake、Illinois、美国、60030
- Acpru /Id# 279405
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
- Body weight ˃ 45 kg at the time of screening and upon initial confinement.
- A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG
Exclusion Criteria:
- History of suicidal ideation within one year prior to study treatment administration and/or history of suicidal behavior or non-suicidal self-injury within two years prior to study treatment administration as evidenced by any "yes" answer to questions on the Columbia-Suicide Severity Rating Scale (C-SSRS) at the screening visit or upon initial confinement.
- Current or past history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, genitourinary, endocrine (including diabetes mellitus, thyroid disorders), malignancy, hematological, immunological, neurological, or psychiatric disease that, , in the opinion of the investigator, could compromise either participant safety or the results of the trial.
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:ABBV-1042 or Placebo-Group 1
Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
Oral Solution Oral Solution |
|
实验性的:ABBV-1042 or Placebo-Group 2
Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
Oral Solution Oral Solution |
|
实验性的:ABBV-1042 or Placebo-Group 3
Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
Oral Solution Oral Solution |
|
实验性的:ABBV-1042 or Placebo-Group 4
Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
Oral Solution Oral Solution |
|
实验性的:ABBV-1042 or Placebo-Group 5
Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
Oral Solution Oral Solution |
|
实验性的:ABBV-1042 or Placebo-Group 6
Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
Oral Solution Oral Solution |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants Experiencing Adverse Events
大体时间:Up to approximately 32 days
|
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
Up to approximately 32 days
|
|
Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements
大体时间:Up to approximately 3 days
|
Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed. |
Up to approximately 3 days
|
|
Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
大体时间:Up to approximately 3 days
|
The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior. |
Up to approximately 3 days
|
|
Number of Participants with Abnormal Change in Physical Examinations
大体时间:Up to approximately 3 days
|
Number of participants with abnormal change in physical examinations in areas like cardiovascular, respiratory, and neurological systems will be assessed. |
Up to approximately 3 days
|
|
Number of Participants with Change from Baseline in Electrocardiogram (ECG)
大体时间:Up to approximately 3 days
|
12-lead resting ECG will be recorded. |
Up to approximately 3 days
|
|
Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed
大体时间:Up to approximately 3 days
|
Number of participants with abnormal change in clinical laboratory test results like hematology will be assessed. |
Up to approximately 3 days
|
|
Maximum Plasma Concentration (Cmax) of ABBV-1042
大体时间:Up to approximately 3 days
|
Cmax of ABBV-1042 |
Up to approximately 3 days
|
|
Time to Cmax (Tmax) of ABBV-1042
大体时间:Up to approximately 3 days
|
Tmax of ABBV-1042 |
Up to approximately 3 days
|
|
Apparent terminal phase elimination constant (β) of ABBV-1042
大体时间:Up to approximately 3 days
|
β of ABBV-1042 |
Up to approximately 3 days
|
|
Terminal Phase Elimination Half-Life (t1/2) of ABBV-1042
大体时间:Up to approximately 3 days
|
t1/2 of ABBV-1042 |
Up to approximately 3 days
|
|
Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCt) of ABBV-1042
大体时间:Up to approximately 3 days
|
AUCt of ABBV-1042 |
Up to approximately 3 days
|
|
Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of ABBV-1042
大体时间:Up to approximately 3 days
|
AUCinf of ABBV-1042 |
Up to approximately 3 days
|
合作者和调查者
赞助
调查人员
- 研究主任:ABBVIE INC.、AbbVie
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.